🧪 Beta — BiohacksAI is under active development. Data and features may change.
B

Dolutegravir vs vesamicol

Mechanistic comparison of Dolutegravir and vesamicol based on molecular target overlap from BindingDB and ChEMBL binding affinity data.

2
Shared Targets
50%
Jaccard Similarity
54%
IDF-Weighted Similarity
Jaccard measures raw target overlap. IDF-weighted downweights promiscuous hub targets (e.g. CYP enzymes) that bind many compounds non-specifically.

Evidence Comparison

Dolutegravir
Evidence Score
298
PubMed Studies
View full profile →
vesamicol
Evidence Score
0
PubMed Studies
View full profile →

Target Overlap

Dolutegravir and vesamicol share 2 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.500 means 50% of the combined target set is bound by both compounds. The IDF-weighted score of 0.544 accounts for non-specific binding to metabolic enzymes.

Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.

Frequently Asked Questions

What do Dolutegravir and vesamicol have in common?
Dolutegravir and vesamicol share 2 molecular targets with a Jaccard similarity of 50%. Both bind overlapping sets of proteins based on BindingDB and ChEMBL binding affinity data.
Can Dolutegravir and vesamicol be combined?
Dolutegravir and vesamicol share 2 molecular targets, suggesting potential pathway overlap. Combination use should be evaluated with a qualified healthcare professional. BiohacksAI does not provide medical advice.
Which has more research: Dolutegravir or vesamicol?
In the BiohacksAI corpus: Dolutegravir has 298 PubMed-indexed studies, vesamicol has 0 studies.

Related Comparisons

Similar to Dolutegravir

Dolutegravir vs siramesine2 targetsDolutegravir vs ditolylguanidine2 targetsDolutegravir vs 11csa45032 targetsDolutegravir vs 52 targetsDolutegravir vs amantadine2 targets
View full Dolutegravir profile →View full vesamicol profile →Browse all substances →